Staining of Teeth by Tetracycline - A Case of Product Liability by Wallach, Jeffrey J.
DePaul Law Review 
Volume 18 
Issue 2 Issue 2 & 3 Summer 1969 Article 12 
Staining of Teeth by Tetracycline - A Case of Product Liability 
Jeffrey J. Wallach 
Follow this and additional works at: https://via.library.depaul.edu/law-review 
Recommended Citation 
Jeffrey J. Wallach, Staining of Teeth by Tetracycline - A Case of Product Liability, 18 DePaul L. Rev. 539 
(1969) 
Available at: https://via.library.depaul.edu/law-review/vol18/iss2/12 
This Article is brought to you for free and open access by the College of Law at Via Sapientiae. It has been 
accepted for inclusion in DePaul Law Review by an authorized editor of Via Sapientiae. For more information, 
please contact digitalservices@depaul.edu. 
STAINING OF TEETH BY TETRACYCLINE-A CASE
OF PRODUCT LIABILITY
JEFFREY J. WALLACH*
HE LAST two decades have seen a tremendous proliferation of
drugs for the treatment of an endless variety of disorders "that
flesh is heir to." The use of many of these drugs, however, has
been attended by complications. Side effects have ranged from simple
gastro-intestinal upsets, such as nausea, vomiting, and diarrhea, to
reactions so severe that the consequences have been more serious than
the disease the drug was intended to cure. These untoward results
have been responsible for evolutionary changes in government super-
vision of research, development, and marketing of drugs under the
Food and Drug Administration in order to better protect the consumer.
There have also been changes in the attitudes of the courts, which have
not only enabled the plaintiff who was injured by such products to
recover for his injury, but have also extended the meaning of "pro-
ducts" from those that are strictly "manufactured" to those that are
merely "processed," such as blood used in transfusions.' Theories of
both product and tort liability have been extended in drug cases, some
of which involved thousands of plaintiffs. Aralen, a drug used for the
treatment of arthritis, resulted in blindness in many cases. Similarly,
Thalidomide, when used by pregnant women to induce sleep, apparently
caused thousands of deformed, limbless babies, and MER/29, used to
reduce blood cholesterol (associated with heart disease), caused nu-
merous cases of blindness from cataract formation.
The late 1940's and 1950's were marked by the appearance of the
new miracle drugs known as antibiotics, developed for the treatment
* DR. WALLACH is an Assistant Professor of Clinical Surgery at New York Medical
College. He received his D.D.S. from the University of Pittsburgh and his LL.B. from
New York Law School. He was Chairman of the Ethics Committee of the Eastern
District Dental Society (1968), and is currently a member of the bar of the State of
New York. The author is currently a practitioner of dentistry and law, with separate
offices in New York City.
'Perlmutter v. Beth Davis Hosp., 308 N.Y. 100 (1954). This case concerned itself
with hepatitis caused by contamination in the blood which was undetectable until after
the harm had been done.
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of infections. Hitherto virulent, life-threatening, and often fatal infec-
tions of the human body yielded to the persuasion of the broad
spectrum wonder drugs.' This paper deals with one particular group:
antibiotics, tetracyclines, and one particular side effect: irreversible,
intrinsic tooth staining, frequently accompanied by disfiguring changes
in the structure of the teeth. The problem is presented in two parts: the
medical-dental picture and the legal picture.
To the best of my knowledge, no cases dealing with this problem
have been tried in the courts as yet. The delay is probably due to cer-
tain unique features: the injury is not disclosed until about seven years
after the administration of the drug; it appears only in children; and the
disfigurement is not regarded as serious until the child approaches
maturity when esthetics of the teeth becomes more meaningful and the
staining is of more consequence. Consider, therefore, that years could
conceivably elapse before a genuine concern with the condition arises.
For example, a child who took this drug in 1954, when he was about
one year old, is now fifteen and first becoming concerned with the ap-
pearance of his teeth. Some attorneys, therefore, may have already
been consulted on this problem, and it is just a question of time until
litigation materializes. This paper will attempt to acquaint attorneys
with the particular knowledge necessary to evaluate the merits of this
type of forensic problem.
THE MEDICAL-DENTAL PICTURE
Tetracycline was developed between 1946 and 1948 by Lederle
Laboratories, and released to the medical professions at about the same
time. In October, 1958, a group of researchers and investigators at
Harvard were treating children afflicted with cystic fibrosis of the pan-
creas. Cystic fibrosis is a children's disease with many complications.
Besides the lesions of the pancreas, there may be pulmonary complica-
tions and other infections requiring continuous treatment with antibi-
otics over a period of many years. Uninterrupted treatment extending
over eight and nine years was reported by these doctors. In those pa-
tients who were treated with tetracycline, they noted a staining of
the teeth ranging from yellow to brownish gray. The discoloration of
2 Broad-spectrum drugs are those drugs where the use of a single drug to treat many
varieties of microbes is effective, as contrasted with an effective range of treatment of
only one or two varieties of bacteria.
3 Schwachman, The Effect of Long-term Antibiotic Therapy in Patients with Cystic
Fibrosis of the Pancreas, [1958-1959] ANTIOBIOT. ANN. 692.
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the teeth was markedly disfiguring and was seen to become darker
with age. The stain appeared as a band of color horizontally striping
the tooth. This side effect was later noted by others who utilized the
unique visible deposition of tetracycline in teeth to facilitate a study
of the development of teeth. By examining teeth under a microscope
after extraction and preparation, it was possible, by correlating the
stained striped areas with the time intervals of serial administration of
the drug, to "tag" the stages of development of individual teeth and
thereby to plot tooth growth step by step.4
The growth of teeth can be compared with the growth of a tree.
After a tree has been felled, one may examine the rings of the stump
and equate the size, position, and thickness of each ring with the an-
nual history of the tree. Thin rings, for example, indicate "lean" years
caused perhaps by drought or insect infestation which sapped the
growing power of the tree. Similarly, injury to the tree caused by fire,
physical trauma such as a blow from an axe, or other forces would be
indicated by involutions or distortions in the rings formed in that
growth period and even in subsequent years, until the injury was
healed. A tooth develops in much the same way, except that the tooth
is not laid down in concentric rings. It starts growing at the biting edge
and then adds layer after layer to its length, until the whole tooth de-
velops through its crown to the final termination at the end of the root.
Every significant trauma or serious illness which saps an individual's
strength, changes his stress patterns, and interferes with his metabolism,
is reflected in the growing tooth: Its development is adversely affected
while the body fights the disease, thereby "neglecting" the proper
tooth growth. Direct trauma, such as a blow injuring the tooth, will
affect growth and development at that point in time. It is possible
much later in life to fix the date of trauma, with reasonable certainty,
by noting the position of the abnormality on the tooth, and then com-
puting the individual's age at that stage. of the tooth development. So
the teeth have their "lean" years too. Most of tooth growth takes
place deep in the bones of the jaws before the tooth even appears in
the mouth, where it finally arrives by the process of eruption. By the
time a tooth normally erupts, it has been subjected to all the "slings
and arrows of outrageous fortune." In fact, the deciduous teeth start
to develop while the child is still in the fetal stage, and the "slings and
arrows" even penetrate the mother's womb. In a recent study, thirteen
4 Boyne & Miller, A Study of Tooth Development by Tetracycline-Induced Fluores-
cence, 40 J. DENT. REs. 1079 (1961).
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children were examined whose mothers had been treated with erythro-
mycin (an antibiotic) and/or tetracycline during pregnancy. By cor-
relating fetal growth with the stained areas in the teeth of these chil-
dren, it was determined that calcification of deciduous teeth begins dur-
ing the middle of the fourth month of pregnancy and continues to term
(the normal end of pregnancy). Mothers who had received tetracycline
from the fourth month to term gave birth to children with discolored
teeth. Mothers who had received tetracycline prior to the fourth month
had children with normal teeth. Mothers who had been treated similarly
with erythromycin also had normal children.'
The role of tetracycline in tooth staining was not just deduced by
the circumstances, but was induced by particulars revealed in an ex-
periment utilizing the ultra-violet spectrum analysis of material
chemically extracted from stained teeth.' This elegant technique of
preparing the teeth and the spectral analysis of the material extracted
is excellently described by the researchers, leaving no doubt as to the
culpability of tetracycline. They clearly state that "Tetracycline may
now be the commonest cause of enamel hypoplasia in young children."7
It was further determined in this experiment that the amount of tetra-
cycline administered, not the length of time during which it was ad-
ministered, is the determining factor of the degree of the discoloration.
The higher the individual dose the greater the discoloration. If the
dose was high enough, yet still within the usual therapeutic levels used
in ordinary treatment, there was staining not only in the area of min-
eralization (the area maturing at that time) but also extending for-
ward to the area of incomplete mineralization (the area about to be
matured) and backward to the area most recently mineralized.
The staining itself occurs immediately upon the administration of
tetracycline, but of course the longer the drug is administered the more
of the tooth that is involved. The immediacy of this side effect has
been established by an experiment in which this deposition in the
developing teeth of dogs was microscopically observed in a comparison
of dogs sacrificed only a day after they had received a single dose of
5 Kline, Blattner & Lunin, Transplacental Effect of Tetracyclines on Teeth, 188
J. Am. MED. Ass. 178 (1964).
0 Wallman & Hilton, Teeth Pigmented by Tetracycline, LANCET, April, 1962, at 827.
7 Bevelander & Nakahara, The Effects of Diverse Amounts of Tetracycline on Fluores-
cence and Coloration of Teeth, 68 J. PEDIAT. 114 (1966).
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tetracycline with those that had received as much as twenty-four weeks
exposure.
8
Pigmentation and faulty enamel in the teeth of children results from
the use of the drug by the mother while the child is still prenatal. The
consequence is an initial light yellow coloration gradually turning brown-
ish with increasing age. Exposure to light intensifies the coloration.'
The staining of teeth also extended well into the adult or permanent
dentition. 0
The part of the tooth that can be seen when looking into the mouth
is called the clinical crown. This is usually all that can be seen of the
tooth by the casual observer. From birth until about the age of eight
the child is developing the clinical crown of most of his permanent
teeth. Therefore, the first eight years of life are the years that are most
crucial in the formation of the crowns. The third molars (wisdom
teeth) are susceptible for the longest period, as they continue to un-
dergo crown development until almost the age of fifteen.
The harmful effect of the drug is essentially a cosmetic one; however,
there have been reports not only of staining, but also changes in the
structure of the teeth (hypoplasia).1 Indicative of -this are the defects
in enamel formation, which may be classified as enamel hypoplasia and
enamel hypomaturation.' 2 Enamel hypoplasia may be defined as a dis-
turbance in enamel matrix formation, whereby the actual growth of
the tooth is disturbed. The depth and shape of the deformity depends
upon the part of the tooth enamel affected and the duration of the dis-
turbance coupled with the severity of the trauma to the ameloblasts
(the enamel-forming cells). Defects of hypoplasia are defects of shape
8 Owen, The Effect of Administering Tetracycline to Young Dogs with Particular Refer-
ence to Localization of the Drug in the Teeth, 8 ARCH. ORAL. BIoL. 715 (1963).
9 Martin, Complications of Antibiotic Therapy in the Management of Bacterial Infec-
tions, LA ECET, April, 1966, at 162.
10 Witkop & Wolf, Hypoplasia and Intrinsic Staining of Enamel Following Tetracycline
Therapy, 185 J. Am. MED. Ass. 100 (1963). Children who were between the ages of nine
and eleven months old when the drug was administered showed staining of the teeth and
hypoplasia of the enamel involving the biting edge of the incisors (front six teeth upper
and lower) and biting surfaces of the first molars. Dosage varied from 250-500 mgm per
day, or from 20-75 mgm per kilogram per day (about a minimum therapeutic dose).
Those with the higher dose had severe hypoplasia. Weyman & Porteus, Discoloration of
Teeth Possibly Due to Tetracyclines, 113 BRIT. DENT. J. 51 (1962). Permanent teeth only
were affected when the tetracycline had been administered after eleven months of age.
11 Supra note 7.
12 Via, Enamel Defects Induced by Trauma During Tooth Formation, 25 ORAL Suac.
49 (1968).
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and contour and appear as wavy or pitted surfaces. As opposed to a
disturbance in the enamel matrix, enamel hypomaturation is the result
of a disturbance in calcification. As such, growth of the tooth is not
disturbed, but its quality is abnormal. It is seen as an opacity or dis-
coloration in a section of improperly calcified enamel. With hypo-
maturation there is no difference in enamel thickness or contour such
as that seen in areas of enamel hypoplasia. Combinations of the effects
of hypoplasia and hypomaturation may occur in the same tooth as a
result of the same etiologic incident. Incidents of surface defects and
staining are even more disfiguring than those involving staining alone.
Teeth are classified for the purposes of identification by an inter-
nationally accepted method. There are sixteen teeth in each jaw in the
adult dentition. They are numbered from the midline of the jaw from
one to eight, right and left, upper and lower in the following manner:
The teeth in both the upper and lower jaws closest to the midline are
called central incisors (designated by the number 1); the teeth im-
mediately adjacent posteriorly are called the lateral incisors (desig-
nated by the number 2); next are the cuspids or eye teeth (designated
by the number 3); then, a pair of bicuspids (the first of which is desig-
nated 4 and the second, 5); then, the first, second, and third molars
(designated 6,7, and 8 respectively). The mouth, as the observer views
it, is divided into four quadrants, a vertical line dividing the right and
left halves and a horizontal line dividing upper from lower. Thus, the
designation 3_J would be the subject's upper right cuspid and the
designation L4 would be the upper left first bicuspid; [-6, the lower
left first molar and 27, the lower right lateral incisor. The following
table depicts the ages at which crown growth starts and is completed
and when the tooth is erupted into the mouth for each of the teeth in
the permanent dentition; it, therefore, represents the years in which
the structure and appearance of the crowns may be affected.
Picture, if you will, a great number of boys and girls, of whom there
must be thousands by this time, with gray-brown, mouse-colored teeth,
with or without pits and other surface defects. Every time they smile
or even speak they expose to public view a part of themselves that our
society, rightfully or wrongfully, has come to value chiefly for appear-
ance. Mouse-colored brown teeth inhibit the would-be smiler and
diminish his personality in the eyes of the beholder. Think of the young
adult or mature individual whose entire life has been dulled and
hampered because of his grotesque teeth, or the theatrically talented
[Vol. XVIII: 539
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DEVELOPMENT AND ERUPTION OF THE CROWN OF THE PERMANENT
TOOTH IN THE HUMAN DENTITION
15
Age at which Age at which crown Age at which
crown starts is completely crown is fully
Tooth developing developed erupted
MANDIBULAR (LOWER) TEETH
111, 616 6 months 3.75-4.0 yrs. 6-7 yrs.
212 11 months 4.25 yrs. 7-8 yrs.
313 2 yrs. 6 yrs. 7-8 yrs.
414 2.5 yrs. 7 yrs. 11-12 yrs.
515 3.75 yrs. 7.75 yrs. 11-12 yrs.
717 4 yrs. 8.25 yrs. 12 yrs.
818 10 yrs. 14.75 yrs. 18-21 yrs.
MAXILLARY (UPPER) TEETH
1ll, 616 11 months 4.5 yrs. 7-8 yrs.
212 20 months 5.5 yrs. 8 yrs.
313 2 yrs. 6.5 yrs. 9.5 yrs.
414 3 yrs. 7.5 yrs. 10.5-11.5 yrs.
515 4 yrs. 8.5 yrs. 11 yrs.
717 4 yrs. 8.25 yrs. 12 yrs.
818 9.25 yrs. 14.75 yrs. 18-21 yrs.
individual whose career is thwarted, or the salesman whose appeal is
dimmed. Further, not only may the cosmetic value of the teeth be
ruined, but their function and integrity may also be hampered.14 How
can this condition be prevented? By refraining from the administration
of tetracycline during at least the first eight years of life! Damage done
before birth affects only the teeth that are shed almost entirely by
13 This table was interpolated from data in Nolla, The Development of the Permanent
Teeth, 27 J. DENT. CHILD. 254 (1960).
14 In my own personal dental practice, I have treated two patients age thirteen who
could be archetypes of this type of disfigurement. One of them is also a victim of ram-
pant caries, a condition in which the teeth decay at such a rapid rate that they defeat
all effort at restoration, as they crumble away almost before your eyes. The latter patient
developed from thirty to forty individual cavities in a four month period, and it was
necessary to crown (cap) several of his teeth before he was eleven, since it was impos-
sible to restore them with routine metallic fillings. It is possible that there is a connec-
tion between his lack of resistance to decay and the changes wrought in his tooth struc-
ture by tetracycline. I have noticed when drilling on his teeth that the texture seems much
softer than normal tooth structure. Although this is only one case, it may be reinforced
by further investigation and by comparing the clinical history of other similarly afflicted
patients.
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eleven years of age, therefore, prenatal precautions are really not too
important. How do we correct the disfigurement that has already been
caused? It is impossible to reverse the color change; so, the only course
left is to cap all the teeth involved.
Let us confine ourselves to the permanent dentition only. The teeth
that are ordinarily exposed to the world in speaking and smiling are
usually the incisors and bicuspids. There are six anterior incisors in
each jaw and four bicuspids in each jaw-a total of twenty teeth. In
some mouths the first molars may also be readily seen, so that these
individuals may require four additional crowns. A child's teeth are
extremely sensitive to bulk removal of the outer protective layer of
enamel. The nerve in the center of the tooth and its accompanying
blood vessels shrink as the tooth grows older, and bulk removal may
be accomplished when the nerve has matured and shrunken without
fatal trauma to the vital structures of the tooth. If the nerve is injured
seriously, the tooth "dies" and abscess results, requiring extraction of
the tooth or root canal treatment. Crown restorations, requiring re-
moval of large amounts of the outer surface of the tooth should there-
fore be postponed until the patient is about the age of fifteen. The dis-
figurement before this age will probably not be too handicapping any-
way. The cost of this type of dental work currently averages $125.00
per tooth, or a total of about $2,500.00. Add to this the pain and suffer-
ing attendant upon as many as sixty injections of a local anesthetic
into the sensitive gums; dental appointments for intensive treatment,
numbering from thirty to forty individual appointments spread out
over a year at weekly intervals; the humiliation, shame, and discom-
fort of wearing temporary crowns (which at best are neither pretty nor
comfortable); the loss of the use and function of the natural dental
apparatus; and the increased care and consideration with which the
final porcelain crown restorations must be treated for the rest of the
patient's life (since they are not as strong as natural teeth and break
more easily, occasionally requiring replacement at additional cost).
Now, multiply all that money, and all those troubles and woes by at
least three. Now we have a total of $7,500.00 in special damages. This
is necessary because the gums continuously shrink throughout life, re-
quiring that the teeth be recapped at least three times. For example, the
gums of our young patient will shrink away as he matures, and the
necks of the teeth that were originally covered by the gums and are
[Vol. XVIII:539
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not covered by the caps will be exposed once again in all their mouse-
gray glory. So the whole thing will have to be done again when the
patient is about twenty-one years old, and possibly again at thirty-five.
The rate of gum shrinkage is more rapid in youth, slows down in the
thirties and forties, and speeds up again thereafter. It is even conceiv-
able that the whole process will have to be repeated a fourth time
during a lifetime, for the requirement of esthetic teeth certainly does
not lessen as life goes on.
THE LEGAL PICTURE
The theory of product liability has undergone explosive changes in
recent years, which Dean Prosser calls "the most rapid and altogether
spectacular overturn of an established rule in the entire history of the
law of torts."' 5 Before the 1916 case of MacPherson v. Buick Motor
Co.' was adopted by all jurisdictions, almost half a century had
passed. But in just about the eight years since the New Jersey Supreme
Court in Henningson v. Bloomfield Motors17 held that a consumer not-
withstanding privity and negligence could recover against a manu-
facturer of a defective product for breach of an implied warranty,
more than thirty states have adopted strict liability.' It is almost im-
possible to avoid some notice of peripheral cases dealing with sales,
contracts, and liability generally. However, my purpose here is not to
write a learned treatise on product liability, but an analysis of its appli-
cation to the tetracycline tooth staining situation.
The field of drug liability has been examined in a most complete and
exhaustive manner by Paul Rheingold, 19 although his article preceded
the Restatement (Second) of Torts, section 402A, which has been of
great influence in the field. For convenience I will use his topics as a
checklist, and simply update his effort with more recent cases and
articles, leaving the discussion of the historical and philosophical
questions to his monumental article.
15 Prosser, The Fall of the Citadel, 50 MiNN. L. REv. 791, 793 (1966).
16217 N.Y. 382, 111 N.E.2d 1050 (1916).
17 32 N.J. 358, 161 A.2d 69 (1960).
18 Supra note 15, at 805.
19 Rheingold, Products Liability-The Ethical Drug Manufacturer's Liability, 18 RUT-
GERS L. REV. 947 (1964).
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OPERATION OF DRUGS; TOXIC REACTIONS AND SIDE EFFECTS
From a pharmacological viewpoint we are not concerned in this
case with the varieties of reactions (intolerances and allergies) which
may occur in individual patients who ingest this drug, nor are we con-
cerned with those effects caused by overdosage, nor change in potency
either from synergistic or antagonistic effects of other materials. We
are dealing with a specific reaction of the drug common to all who use
it. The injury varies only quantitatively with the length of time ad-
ministered and the size of the dose. Even though therapeutic norms
are observed in both time and dose, injury exists in all cases in which
teeth are being developed. 0 Even the rule of good medical practice
which dictates that the physician in medicating a patient should be
alert for adverse reactions does not apply here, for tooth staining is
not evident until months or even years after the drug has been used.
Now that the side effect is common knowledge the "good practice rule"
that applies is that the drug should not be used unless absolutely neces-
sary. Other antibiotics accomplishing the same purpose as tetracycline,
without the side effect, are available. It is conceivable that if a choice
is available, a practitioner would be liable for using or prescribing a
drug which results in harm, if he ignores the consequences of the contra-
indicated drug.
DEVELOPMENT OF NEW DRUGS; ROLE OF THE MANUFACTURER AND THE
FOOD AND DRUG ADMINISTRATION
As is the case with almost all other drugs developed in the United
States, tetracycline was developed by one manufacturer who was
primarily concerned with its researching, testing, and marketing and
who had complete control over these factors, complying at the same
time, where applicable, with government supervision under the FDA.
The duty rests with the manufacturer to choose his investigators with
care and to examine their results.
Stages of development
Ordinarily, initial experimentation involves the use of animals.
Rheingold notes that animals are not reliable as to adverse effects,
since one species of animal may react differently than another, and
20 Supra notes 5 and 7.
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animal reactions may not be conclusive as to reactions in man.2 1 How-
ever, tetracycline animal research produced conclusive evidence that
staining of teeth was an unvarying side effect and should have served to
warn the manufacturer to be alert for the same side effect in man.
Staining had been observed in dogs22 and in rats..2 3 Both of these are
common laboratory animals, and were quite likely used by the manu-
facturer in his studies. The reports of staining in dogs and rats did
not appear until 1963 and 1966, eighteen years after the drug was
released, but an examination of the manufacturer's data will disclose
whether these animals were used and the side effect disregarded or not
noted.
Adequacy of testing and reports
As to the clinical use of the drug and its adverse effects on humans
there is earlier evidence. In 1958 Schwachman and others, using tetra-
cycline supplied by the manufacturer for their experiments, reported
tooth staining.24 This date is six years before the manufacturers warned
the medical profession of the adverse reaction, an apparently uncon-
scionable delay. Rheingold notes that:
[I]t is no longer an uncommon phenomenon for side effects to turn up only after a
drug has been marketed and widely used, and then to be of a serious enough na-
ture to justify either its withdrawal from the market or the imposition of stringent
restrictions to its use. The question invariably raised in this situation is whether
the clinical trials were adequate ... or shoddily done by the drug houses and their
investigators . . . or data fraudulently created either to enhance the efficacy or
camouflage adverse reactions. 25
FOOD AND DRUG ADMINISTRATION SUPERVISION
Tetracycline is one of the group of drugs (antibiotics) that is super-
vised under different rules than those applied to other drugs. Specifi-
cally they are certified in batches.26 Unless one of this group bears a
batch number it will be considered misbranded. A drug will also be
considered misbranded if adequate warning and directions are not
21 Supra note 8.
22 Supra note 8.
2 3 Supra note 7.
24 Supra note 3.
25 Supra note 19, at 958-59.
26 21 U.S.C. § 357 (1958).
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given where use by children is involved." If the question of misbrand-
ing can be established, actual violation of the statute may be pleaded in
establishing a prima facie case. Rheingold, in considering the question
of injury by established drugs, divides injuries into those caused by
impure drugs and those caused by pure drugs.
Impure drugs are those drugs sold other than as the manufacturer intended, and
containing deleterious impurities. Pure drugs, on the other hand, are those sold
as the manufacturer intended, but with the harm arising as a side effect because of
some inherent quality, or perhaps, because of some constitutional peculiarity on
the part of the user.28
Tetracycline cases fall into the pure drug category.
Let us examine further the chronology of tetracycline development,
and add pertinent data to that already disclosed. Some typical generic
names of tetracycline derivatives and their trade names are shown in
the following chart.
GENERIC NAME TRADE NAME
Oxytetracycline Terramycin






There are additional derivatives which will be enumerated later, but
suffice it to say that the literature indicates that all of them stain teeth.
However, it may be necessary to prove the adverse reaction in those
that are not specifically mentioned in the literature. Schwachman re-
ported staining with the two most important derivatives, chlortetracy-
Cline and oxytetracycline.29 As previously noted, according to Lederle
Laboratories, chlortetracycline hydrochloride was the first of the class
developed. It was released to the medical profession in 1948, after be-
ing developed in the period from 1946 to 1948. It was followed shortly
by other releases of tetracycline derivatives from other manufacturers.
At the present time there are at least eleven derivatives manufactured
under various trade names listed in the Physician's Desk Reference
2721 U.S.C. § 352(f) (1958).
28 Supra note 19, at 970.
29 Supra note 3.
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(PDR). 80 From the development and release in 1948 until the 1964
issue of PDR there was no warning given by any manufacturer as to
the adverse reaction of tooth staining. In 1964, the warning blossomed
forth. In each of the manufacturer's product circulars, the warning is
worded almost indentically. The following is Pfizer's warning. (The
others may vary slightly, but generally only as to the name of the
drug.)
WARNING. Oxytetracycline may form a stable calcium complex in any bone-forming
tissue with no serious harmful effects reported thus far in humans. However, use
of oxytetracycline during tooth development (last trimester of pregnancy, neonatal
period, and early childhood) may cause discoloration of the teeth (yellow-gray-
brownish). This effect occurs mostly during the long-term use of the drug, but it
has also been observed in usual short-term treatment courses.3 '
The trade names follow with the page numbers in PDR (1967) at











Tetracyn (Roerig) 1015, 1017
Tetrun (United Labs) 1162
INJURY CAUSED BY ESTABLISHED DRUGS
Full warning of side effects
The manufacturers did not issue any kind of a warning as to tooth
staining until 1964. Cases caused by staining after the warning was
finally issued will not arise until about 1971, since the children who
first took the drug in 1964 will have to wait at least seven years for
their affected teeth to erupt into the mouth in order that the stain be
evaluated. These cases will be the ones in which there will be the most
difficulty establishing liability. However, there are some theories by
which we may still hopefully reach the jury.
80 PHysIciAN's DEsK REFERENCE TO PHARMACEUTICAL SPEcIALTIES AND BIoLoGicALS
(1967) (hereafter referred to as PDR).
81 Label appearing on oxytetracycline, a drug produced by Pfizer.
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The negligence action
In order to establish negligence where there has been adequate warn-
ing, it would be necessary to prove that the manufacturer was negligent
in distributing the product in the first place, due to the unreasonable
risk of harm, regardless of warning. 2 This theory of negligence relies
on "design liability."
There are, however, suggestions in cases and-in the views of leading commentators
on tort law that if a product is created that is inherently dangerous and it is ...
probable that no amount of warning will prevent it from being used by a substantial
number of consumers, the manufacturer would be liable for marketing the ill-
designed product.3 3
It is likely that this rule might be applied where the drug is particularly
useful in cases of infection and where a large number of consumers are
adversely affected. The case of Carmen v. Eli Lily & Co.,34 however,
held that the defendant was not liable, relying on the fact that Lily had
warned of the possibility of paralysis though only forty cases of paral-
ysis and two deaths were cited in 100,000 instances of use (.042 % side
effects). But tetracycline apparently affects one hundred percent of
the users, and the rule of design liability should apply rather than
Carmen. A case in which the court spoke by way of dictum voices this
view. The case involved a hazardous airplane switch and although the
judgment was for the defendant, the dictum stated that a defendant
could be found to have created an unreasonable risk even though it
was known and obvious.3
Warranty action
Dealing with a pure product manufactured and distributed as in-
tended by the manufacturer, it would seem easier to maintain an
action for warranty than one for negligence, even where the manu-
facturer has warned of possible harm. Warranty can be said to be an
action in strict liability and negligence need not be shown on the part
of the defendant. Some stumbling blocks appear in this type of action,
two of which, sale and privity, have received some attention from the
courts. Some courts have denied the liability by insisting on the proof
32 Supra note 19, at 982.
83 Supra note 19, at 982.
8 109 Ind. App. 76, 32 N.E.2d 729 (1941).
35 Goldsmith v. Martin Marietta Corp., 211 F. Supp. 91 (D. Md. 1962).
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of a technical sale. Perlmutter v. Beth David Hospital held that blood
received during a transfusion was a service, not a sale." But when the
drug was administered by a physician, the opposite result occurred,37
the court observing that: "Clearly it is the patient and not the doctor
who is the ultimate consumer of the vaccine .. . [The] implied war-
ranties ... run to the benefit of the persons intended to be the con-
sumers."
38
There are additional new cases that have allowed recovery. In a
recent case, the transfusion of blood at the hospital was held to be a
sale, and the court said that the discoverability of serum hepatitis in
blood was a fact question for the jury even where not discoverable by
existing scientific means.39 The court went on to state: "The modern
tendency of the law is to shift the burden from the innocent victim to
the community at large and to distribute the losses suffered by the
individual among all who benefit."4
The Uniform Commercial Code may also apply here. It states that
there is no intent to "disturb those lines of case growth which have
recognized that warranties need not be confined either to sales con-
tracts or to the direct parties to such a contract."'"
As to privity, the trend of modern case law has been to reject the
continued validity of that concept.4 2 Rheingold advances this provoca-
tive suggestion:
If the argument were to be accepted that adequacy of warning is a negligence
theory concept having no role in warranty actions, then even though a full warning
would negate negligence on the part of the manufacturer, warranty liability would
still be open.43
He also goes on to ask:
Could an argument be made on belhalf of the patient, who otherwise cannot prevail,
that the manufacturer has a duty to warn the patient directly of side effects? That
36 Supra note 1.
37 Gottsdanker v. Cutter Labs, 182 Cal. App. 2d 602, 6 Cal. Rptr. 320 (1960).
I8 Id. at 609, 6 Cal. Rptr. at 324.
39 Community Blood Bank v. Russell, 196 So.2d 115 (Fla. 1967).
40 1d. at 121. See Jackson v. Muhlenberg Hosp., 96 N.J. Super. 314, 232 A.2d 879
(1967).
41 UNIFORM COMMERCIAL CODE § 2-313, comment 2.
4 2 See, e.g., Madouros v. Kansas City Coca-Cola Bottling Co., 230 Mo. App. 275, 90
S.W.2d 445 (1936); Crystal Coca-Cola Bottling Co. v. Cathey, 83 Ariz. 163, 317 P.2d
1094 (1957).
43 Supra note 19, at 985.
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is, can there be a negligent failure to warn when the patient is not informed of the
risk he is running in taking the drug? In the usual situation in which an ethical
drug is prescribed the patient does not receive from his doctor any warning of side
effects or information on the contra-indications which the manufacturer has made;
often indeed the patient does not even know what drug was prescribed. Nor is the
patient likely to obtain information about the side effects of drugs from sources
other than statements from his physician. 44
The concept of "informed consent"4 5 comes into consideration here,
and also the question of whether the intervening conduct of the doctor
serves to relieve the manufacturer from strict liability. A recent case
held that the manufacturer was liable to the patient regardless of any-
thing the doctor may or may not have done in the absence of inter-
vening proximate cause.4" This may not hold true if there has been an
instance of malpractice which may be the proximate cause, although
such a set of facts is difficult to conjure up in tetracycline cases in view
of the freedom a doctor has to use his own judgment as long as it is
within the usually accepted medical standards, as to type of drug, dose,
and indications for treatment. In a case where there is malpractice on
the part of the doctor, there is no reason why the plaintiff could not
join the negligent doctor as a joint tortfeasor.
Absence of warning or inadequate warning of side effects
In this category fall all those cases, probably numbering thousands,
that occurred as a result of tetracycline administered from 1948 to
1964. No warning was made during those years. Certainly, from the
time the first article reporting staining appeared in the medical litera-
ture in 1958, the manufacturer should have been alerted to the side
effects and then had a duty to warn users of these adverse reactions.
The fact that the manufacturer had supplied the tetracycline to these
investigators implies that the manufacturer was reviewing the medical
literature at least in conjunction with those experiments with which
they had such an intimate connection. According to Yarrow v. Sterling
Drug, if the manufacturer, after reviewing publications which indicate
a connection between use of the drug and retinal changes, altered its
literature to warn of ocular complications, this is sufficient to support
a finding that the drug manufacturer knew or had reason to know that
4 4 Supra note 19, at 985.
45See Hirsh, Informed Consent to Treatment, 176 J. Am. MED. Ass. 436 (1961).
46 Yarrow v. Sterling Drug Inc., 263 F. Supp. 159 (S.D. S.D. 1967).
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some persons would be injured by the side effects of the drug.47 With
tetracycline there was a hiatus of six years from report to warning.
Is the publication of warning in the circular which accompanies the
drug, or in PDR, enough warning to be adequate? Yarrow says "no"-
providing literature explaining the use and warning of side effects was
insufficient if the manufacturer's "detail man," who called on the
doctor at four to six week intervals, did not personally bring the side
effects to the doctor's attention. It is the custom of most large pharma-
ceutical houses to send detail men out regularly, and this is surely the
case with many, if not all, manufacturers of tetracycline.
In a 1967 case, the California Supreme Court held: "Where a drug
has not been properly prepared or has been placed on the market and
sold without adequate warning, strict liability for resulting injury may
be found."48 Rheingold comments on this point:
The usual practice for a manufacturer who discovers side effects after marketing a
drug, after reporting to the FDA, is to send out warnings about the adverse re-
actions as soon as possible to doctors and dispensaries. It is at least arguable that
the failure to adhere to this process of notification constitutes a failure to warn,
especially when the causation is fairly certain, the side effects severe, and reason-
able means at hand to send out warnings.49
Side effects unknown-Manufacturer's duty to discover
The theory that a manufacturer should know his own product is a
well-settled one.50 The law imposes a duty on the manufacturer to make
tests and conduct proper investigations. The facts in tetracycline
prove that the manufacturer did conduct tests. Pfizer, in their product
circular, notes, under "Action and Uses for Terramycin," "Terramycin
passes through the placenta into the fetal circulation."51 To make this
statement the manufacturer must have made or authorized tests on
pregnant animals, and examined the fetuses (and possibly the new-
born). The thalidomide cases, which allegedly resulted in deformity to
thousands of babies due to the administration of the drug to their
mothers while pregnant (and caused the withdrawal of the drug in
47M. at 162.
48 Toole v. Richardson Merrell, Inc., 251 Cal. 2d 689, 60 Cal. Rptr. 398 (1967).
4 9 Supra note 19, at 995.
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1961, three years before the tetracycline warnings appeared) should
have demonstrated to those manufacturers the importance of tests on
pregnant animals. An examination of the teeth of the new-born would
have disclosed the defect easily. Yet this was not done-or, perhaps
worse yet, it was done and negligently ignored, or fraudulently con-
cealed.52
STRICT LIABILITY OF THE MANUFACTURER OF DRUGS
In 1965, a strict liability rule was promulgated by the American Law
Institute in the Restatement (Second) of Torts, section 402A, which
has subsequently been adopted in several jurisdictions. Section 402A
provides:
(1) One who sells any product in a defective condition unreasonably dangerous to
the user or consumer or to his property is subject to liability for physical harm
caused thereby to the ultimate consumer, or to his property, if
(a) the seller is engaged in the business of selling such a product, and
(b) it is expected to and does reach the user or consumer without substantial
change in the condition in which it was sold.
(2) The rule stated in subsection (1) applies although
(a) the seller has exercised all possible care in the preparation and sale of his
product, and
(b) the user or consumer has not bought the product from or entered into any
contractual relationship with the seller.
Section 402A is growing in importance and gradually gaining adher-
ents. It clarifies much of the confusion that arises from "warranty"
and frees those who adhere to it from the problems inherent in the
warranty approach.
One recent case that would seem to bear on a tetracycline set
of facts said that contributory negligence is a bar to recovery only if
the plaintiff voluntarily assumes the risk of a known defect (relying
on comment (n) of 402A).11 Another case stated that a complaint
growing out of a breach of implied warranty by the manufacturer stated
a good cause of action even though privity could not be shown. 4 Both
of these cases relied heavily on 402A.
These decisions are coming from courts heretofore reluctant to make sharp changes
in liability law . . . . While the complaints are couched in terms of implied war-
52 Supra note 19, at 958-59
5, McKisson v. Sales Affiliates Inc., 416 S.W.2d 787 (Tex. 1967).
54 Teddler v. Pepsi Cola Bottling Co., 270 N.C. 301, 154 S.E.2d 337 (1967).
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ranty, the courts are approaching the problem as one in torts as is evidenced by
their reliance on the Restatement.55
Strict liability is not absolute liability, but the usual defenses of as-
sumption of the risk and proximate cause do not seem to apply to
tetracycline facts. A plaintiff in a strict liability action was defeated
for failure to show proximate cause where the plaintiff complained
that brown water pouring out of his faucet precipitated a heart attack
because he thought that this was the same water that had gone into his
morning cup of coffee.50 Proximate cause in tetracycline cases should
not present any such problems.
The question of assumption of the risk remains unsettled in recent
cases dealing with section 402A, but it should be remembered in the
tetracycline cases we are concerned with infant plaintiffs, and there-
fore, the capacity of the infant to appreciate such a risk (which is in
most cases nil) is necessarily placed in issue.
A particular problem that arises with 402A cases concerns itself
with comment (k) which deals with "unavoidably unsafe products."
Comment (k) discusses sales of products which "in the present state
of human knowledge are incapable of being made safe for their in-
tended use." In regard to this problem, the Texas Supreme Court con-
cluded that such products:
"properly prepared and accompanied by proper directions and warnings" are not
defective or unreasonably dangerous and the seller of such products ... [again with
the qualifications that they are properly prepared and marketed and proper warning
is given] is not to be held to strict liability for the unfortunate consequences
attending their use. 57
This court went on to find the defendant strictly liable "where the facts
disclose the drug has not been properly prepared ... or has been sold
without adequate and proper warning, strict liability for resulting
injury may be found.1 8 In another MER/29 case with the same fact
pattern as Toole, the federal court in the Southern District of New
York had no trouble finding compensatory damages for the plaintiff,
although the punitive damages were denied by the appeal court.59
55 Parker, Horn, King & Trieber, Torts, in 1967 AINuAL SuRvEY or AmERiCAN LAW
211.
50 Caputzal v. The Lindsay Co., 48 N.J. 69, 222 A.2d 513 (1966).
57 Supra note 48, at 708, 60 Cal. Rptr. at 412.
58 Supra note 48, at 710, 60 Cal. Rptr. at 412.
59 Roginsky v. Richardson Merrell Inc., 378 F.2d 832 (2d Cir. 1967).
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CONCLUSION
A special problem arises with tetracycline cases. Because of the
lapse of time from cause to discovery, proof becomes difficult. None of
these cases can come to light until about seven years have elapsed from
the time of injury. Even if the plaintiff were alert and started to press
his claim at once, he would have to go back seven or eight years to
reconstruct the scene completely. He must prove proximate cause. He
must prove what the drug was, when it was administered, by whom,
and on whose orders. These cases are not like polio vaccine cases, nor
like Thalidomide, MER/29 or Aralen where there was only one manu-
facturer. Here, there is a multiplicity of manufacturers. Pharmacists'
records will have to be searched, as will doctors' records, and perhaps,
even those of hospitals. Each dose must be pinned down to a specific
identifiable product and manufacturer, or all will be lost. There is a
possibility that some attorney will be starting with the oldest cases,
in point of time of injury, in the near future. The drug came on the mar-
ket in 1948. A child who was from eleven months to five years old in
1948 when he took the drug will have stains on his permanent incisor
teeth, and he would now be from twenty to twenty-five years old. An
attorney representing such a client may have to go back twenty years
to prove proximate cause. Of course, there are thousands of cases of
much more recent origin. The most recent case would involve a child
who took the drug eight years ago and has recently erupted a tooth
which shows staining. It makes little sense to prosecute such a case
at this time since the damages would undoubtedly be relatively slight.
A wiser choice is to wait until sufficient permanent teeth have erupted
to evaluate the full extent of the damage. This would require that all
plaintiffs be at least twelve or thirteen years old. That is the age at
which even the second bicuspid has usually erupted into the mouth.
The question of the statute of limitations must be given serious
consideration. The attorney will have to determine for himself, under
the rules of the forum, whether to sue by legal representative before
the statute has tolled, or wait until the disability of infancy has passed
and have the plaintiff sue on his own behalf when he is sui juris. Ac-
cording to my computations, the oldest living possible plaintiff with
damaged incisors is now about twenty-five years old and the time has
run out for him in some if not all jurisdictions.60
6oN.Y. Civ. Prac. § 208 (1963).
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An interesting sidelight has arisen because of the multiplicity of
plaintiffs in drug cases. Attorneys have banded together to form groups
with a common interest. Research common to all and other matters of
common interest are pooled, and the information made available to all
participants.61 Such a group was formed to handle the MER/29 cases.
The kind of joint discovery accomplished by this sort of group has
been attacked with some success in the courts. 2
The question of punitive damages merits consideration. Even though
the damages in a tetracycline case can be extensive, the possibility of re-
covery in exemplary damages exists. The issues of "reckless" conduct,
complicity of corporate officers, and other factors that are essential or
nonessential in such an action are considered in detail in the 1967 An-
nual Survey of American Law.63 There seems to be a tendency of the
courts to protect the corporate defendant from "over kill," as phrased
by Judge Friendly in Roginsky v. Richardson Merrell, Inc.64 citing
Toole v. Richardson Merrell, Inc.65 The decided cases show a regard
by the courts for the possibility of catastrophe litigation causing a
serious economic harm to the corporate defendants in drug cases. Still,
the facts are often of such a compelling nature as to sway the court
from its "floodgate" disposition.
An effort has been made to throw some light on a fairly dark and
esoteric area, and to correlate a fairly narrow segment of drug liability
with the broader field of drug liability generally. It is hoped that this
paper has enhanced the knowledge of the attorney both as to drugs
and dentistry, and clarified and narrowed the issues and law in this
type of case to the benefit of drug manufacturers and plaintiffs alike.
61 Rheingold, Multiple Drug Litigation-The Plaintiff's Viewpoint, 22 FOOD DRUG
COSMET. LAW J. 136 (1967).
62 Costello, Multiple Drug Litigation-The Defendant's Viewpoint, 22 FOOD DRUG
COSMET. LAW J. 147 (1967).
63 Supra note 55.
6 4 Supra note 59.
65 Supra note 48.
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